Favorable Press Coverage Somewhat Unlikely to Impact Vanda Pharmaceuticals (VNDA) Stock Price

Media stories about Vanda Pharmaceuticals (NASDAQ:VNDA) have been trending positive on Thursday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a news impact score of 0.27 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.0833443804196 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

Shares of Vanda Pharmaceuticals (VNDA) opened at $15.25 on Thursday. The firm has a market capitalization of $682.90, a P/E ratio of -47.66 and a beta of 1.28. Vanda Pharmaceuticals has a fifty-two week low of $11.90 and a fifty-two week high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The business had revenue of $41.30 million during the quarter, compared to the consensus estimate of $43.90 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The company’s revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.01) earnings per share. research analysts anticipate that Vanda Pharmaceuticals will post -0.42 EPS for the current fiscal year.

A number of equities analysts recently issued reports on the company. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. Oppenheimer reaffirmed a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Piper Jaffray Companies upped their price target on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, September 14th. BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Vanda Pharmaceuticals has a consensus rating of “Buy” and an average target price of $21.50.

TRADEMARK VIOLATION WARNING: “Favorable Press Coverage Somewhat Unlikely to Impact Vanda Pharmaceuticals (VNDA) Stock Price” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.com-unik.info/2017/12/28/favorable-press-coverage-somewhat-unlikely-to-impact-vanda-pharmaceuticals-vnda-stock-price.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Insider Buying and Selling by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit